We subsequently developed a far more unique probe, [18F]CFA, which was used in The existing review to evaluate dCK action in tumors when handled with a little molecule dCK inhibitor. This probe can also be becoming analyzed within a scientific trial at our institution to evaluate changes in dCK activity pursuing most cancers immunotherapy 18. PET p